Table 2 Clinical and biological features of CLL patients
TP53-wt (n = 16) | TP53-mut (n = 10) | |
|---|---|---|
Total, n | Total, n | |
Age at the diagnosis | ||
median (range), years | 63 (43–81) | 70 (52–85) |
Gender | ||
male | 9 (56%) | 6 (60%) |
female | 7 (44%) | 4 (40%) |
Stage | ||
Binet A | 16 (100%) | 9 (90%) |
Binet B | 0 (−) | 1 (10%) |
Binet C | 0 (−) | 0 (−) |
IGHVa | ||
Mutated | 16 (100%) | 2 (20%) |
Unmutated | 0 (−) | 7 (70%) |
NA | – | 1 (10%) |
CD38b | ||
Negative | 16 (100%) | 4 (40%) |
Positive | 0 (-) | 6 (60%) |
Cytogenetics | ||
Favorable | 0 (-) | 2 (20%) |
Neutral | 16 (100%) | 3 (30%) |
Unfavorable | 0 (−) | 3 (30%) |
NA | – | 2 (20%) |
Follow-up | ||
Median (range), years | 4 (1–6) | 5 (2–19) |
Disease progression, requiring treatment during follow-up | 2 (13%) | 7 (70%) |
TTFT | ||
Median (range), months | 14 (7–22) | 49 (3–212) |
